Intermittent itraconazole therapy for preventing asthma exacerbations

Intermittent itraconazole therapy for preventing asthma exacerbations - Intermittent itraconazole therapy for preventing asthma exacerbations

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006311

Enrollment

Registered

2011-09-10

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

50 mg/day (low dose) itraconazole for 7 days in every month for 12 months 500 mg/day carbocysteine for 7 days in every month for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 20-70 years old

Exclusion criteria

Exclusion criteria: 1)Patients having abnormal shadow on chest X-ray indicative of cough aetiology 2)Patients having wheezing audible 3)Patients having obstructive disorders in pulmonary function testing 4)Patients having severe complications 5)Patients having pulmonary tuberculosis 6)Patients without agreement 7)Patients being pregnant, possible pregnant or breast-feeding a baby 8)Patients judged inappropriate by attending physicians

Design outcomes

Primary

Measure	Time frame
1.Comparison of frequency of asthma attack during next one year between 2 groups. 2.Comparison of frequency of asthma attack between last year and this year. 3.Statistical analysis of two groups against the results of skin reaction tests of Schizophyllum commune.	—

Secondary

Measure	Time frame
1.Comparison of allergological changes and clinical courses.	—

Countries

Japan

Contacts

Public ContactHaruhiko Ogawa

Ishikawa-ken Saiseikai Kanazawa Hospital. The Division of Pulmonary Medicine,

saiseikh@po3.nsknet.or.jp076-266-1060

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026